Razpipadon
Atypical antipsychotic medication
| Razpipadon | |
|---|---|
| [[File: | |
| INN | |
| Drug class | Atypical antipsychotic |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Razpipadon is an atypical antipsychotic medication primarily used in the treatment of schizophrenia and bipolar disorder. It is known for its efficacy in managing both positive and negative symptoms of schizophrenia, as well as its mood-stabilizing properties in bipolar disorder.
Pharmacology[edit]
Razpipadon functions as a dopamine receptor antagonist, particularly targeting the D2 receptors in the brain. It also exhibits antagonistic activity at serotonin receptors, including the 5-HT2A receptor, which contributes to its atypical profile. This dual action is believed to reduce the risk of extrapyramidal symptoms commonly associated with typical antipsychotics.
Mechanism of Action[edit]
The mechanism of action of Razpipadon involves the modulation of neurotransmitter pathways in the brain. By blocking dopamine receptors, it helps to alleviate symptoms such as hallucinations and delusions. The serotonin receptor antagonism is thought to improve mood and cognitive function, addressing the negative symptoms of schizophrenia.
Clinical Use[edit]
Razpipadon is prescribed for the management of schizophrenia and bipolar disorder. It is effective in reducing the frequency and severity of psychotic episodes and stabilizing mood swings. The medication is typically administered orally, with dosage adjustments based on the patient's response and tolerance.
Side Effects[edit]
Common side effects of Razpipadon include weight gain, sedation, and metabolic changes. Patients may also experience dizziness, dry mouth, and gastrointestinal disturbances. Long-term use requires monitoring for potential metabolic syndrome and other health concerns.
Development and Approval[edit]
Razpipadon was developed as part of a new generation of antipsychotic medications aimed at improving the safety and tolerability profile compared to older drugs. It received approval from regulatory agencies after demonstrating efficacy in clinical trials.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
